SPOTLIGHT: Isis gains from big RNAi deal


Alnylam wasn't the only biotech company to score on Wall Street after the announcement of its rich RNAi deal with Roche. Isis Pharmaceuticals stands to gain $26.6 million along with milestones and royalties in the deal, and investors bid up its stock price by 17 percent. Isis licensed its RNAi tech to Alnylam in 2004. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.